CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop small molecules that can effectively protect and repair dopamine-producing neurons in Parkinson's disease. The focus is on creating compounds that can cross the blood-brain barrier and demonstrate safety and efficacy.
Parkinson’s disease (PD) is caused by degeneration and progressive loss of dopaminergic (DA) neurons of the substantia nigra.
In Western countries more than 6 million people live with PD.
Currently no cure for this disease is available, existing therapeutic strategies alleviate PD symptoms but do not influence its cause or in other words do not prevent or slow down degeneration of DA neurons.
Glial cell line-derived neurotrophic factor (GDNF) is one of the few molecules able to protect and repai…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Estonia, TALLINN
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
